Improved survival in red blood cell transfusion dependent patients with primary myelofibrosis (PMF) receiving iron chelation therapy

Hematological Oncology

Volumn 28, Issue 1, 2010, Pages 40-48

  Leitch, Heather A ^a   Chase, Jocelyn M ^a   Goodman, Trisha A ^a   Ezzat, Hatoon ^a   Rollins, Meaghan D ^a   Wong, Dominic H C ^a   Badawi, Maha ^a   Leger, Chantal S ^a   Ramadan, Khaled M ^a   Barnett, Michael J ^a   Foltz, Lynda M ^a   Vickars, Linda M ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Iron chelation therapy; Iron overload; Myeloproliferative disorder; Primary myelofibrosis; Transfusion

Indexed keywords

FERRITIN; HEMOGLOBIN; HYDROXYUREA; IRON CHELATING AGENT;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ERYTHROCYTE TRANSFUSION; FOLLOW UP; HUMAN; IMMUNOMODULATION; IRON CHELATION; LEUKOCYTE COUNT; MYELOID METAPLASIA; PRIORITY JOURNAL; SCORING SYSTEM; SPLENECTOMY; THROMBOCYTE COUNT; BLOOD; CHELATION THERAPY; FEMALE; IRON OVERLOAD; MALE; METABOLISM; MIDDLE AGED; MORTALITY; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; CHELATION THERAPY; ERYTHROCYTE TRANSFUSION; FEMALE; FERRITINS; HUMANS; IRON CHELATING AGENTS; IRON OVERLOAD; MALE; MIDDLE AGED; PRIMARY MYELOFIBROSIS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 77950873995     PISSN: 02780232     EISSN: 10991069     Source Type: Journal    
DOI: 10.1002/hon.902     Document Type: Article

References (64)

1. Mesa RA, Verstovsek S, Cervantes F, sequelaeet al. Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT). Leuk Res 2007; 31(6): 737-740.
2. Michiels JJ, De Raeve H, Berneman Z, et al. The 2001 World Health Organization and updated European clinical and pathological criteria for the diagnosis, classification, and staging of the Philadelphia chromosome-negative chronic myeloproliferative disorders. Semin Thromb Hemost 2006; 32(4 Pt 2): 307-340.
3. Mesa RA, Barosi G, Cervantes F, Reilly JT, Tefferi A. Myelofibrosis with myeloid metaplasia: disease overview and non-transplant treatment options. Best Pract Res Clin Haematol 2006; 19(3): 495-517. (Pubitemid 43863142)
4. Deeg HJ, Gooley TA, Flowers ME, et al. Allogeneic hematopoietic stem cell transplantation for myelofibrosis. Blood 2003; 102(12): 3912-3918. (Pubitemid 37486970)
5. Rondelli D, Barosi G, Bacigalupo A, et al. Allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning in intermediate- or high-risk patients with myelofibrosis with myeloid metaplasia. Blood 2005; 105(10): 4115-4119. (Pubitemid 40656163)
6. Dupriez B, Morel P, Demory JL, et al. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood 1996; 88(3): 1013-1018. (Pubitemid 26333326)
7. Tefferi A. Myelofibrosis with myeloid metaplasia. N Engl J Med 2000; 342(17): 1255-1265.
8. Ganz T. Hepcidin and its role in regulating systemic iron metabolism. Hematology Am Soc Hematol Educ Program 2006; 29-35.
9. Porter JB. Practical management of iron overload. Br J Haematol 2001; 115(2): 239-252.
10. Cohen AR. New advances in iron chelation therapy. Hematology Am Soc Hematol Educ Program 2006; 42-47.
11. Breuer W, Shvartsman M, Cabantchik ZI. Intracellular labile iron. Int J Biochem Cell Biol 2008; 40(3): 350-354.
12. Ghoti H, Amer J, Winder A, Rachmilewitz E, Fibach E. Oxidative stress in red blood cells, platelets and polymorphonuclear leukocytes from patients with myelodysplastic syndrome. Eur J Haematol 2007; 79(6): 463-467. (Pubitemid 350126678)
13. Britton RS, Leicester KL, Bacon BR. Iron toxicity and chelation therapy. Int J Hematol 2002; 76(3): 219-228.
14. Cermak J, Mikulenkova D, Kacirkova P, Michalova K. Modification of WPSS for the time of diagnosis retains its prognostic impact and confirms transfusion dependency as an important parameter affecting survival in early MDS patients with isolated erythroid dysplasia. Blood 2008; 112(11): 584a.
15. Malcovati L, Della Porta MG, Cazzola M. Predicting survival and leukemic evolution in patients with myelodysplastic syndrome. Haematologica 2006; 91(12): 1588-1590. (Pubitemid 46032954)
16. Malcovati L, Germing U, Kuendgen A, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 2007; 25(23): 3503-3510. (Pubitemid 47315575)
17. Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica 2004; 89(10): 1187-1193. (Pubitemid 39390442)
18. Brittenham GM, Griffith PM, Nienhuis AW, et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med 1994; 331(9): 567-573.
19. Porter JB, Cappellini MD, El-Beshlawy A, et al. Effect of deferasirox (Exjade®) on labile plasma iron levels in heavily iron-overloaded patients with transfusion-dependent anemias enrolled in the large-scale, prospective 1-year EPIC trial. Blood 2008; 112(11): 1322a.
20. Rachmilewitz E, Merkel D, Ghoti H, et al. Improvement of oxidative stress parameters in MDS patients with iron overload treated with deferasirox. Blood 2008; 112(11): 924-925a.
21. Leitch HA, Leger CS, Goodman TA, et al. Improved survival in patients with myelodysplastic syndrome receiving iron chelation therapy. Clinical Leuk 2008; 2(3): 205-211.
22. Rose C, Brechignac S, Vassilief D, et al. Positive impact of iron chelation therapy (ct) on survival in regularly transfused mds patients. A prospective analysis by the GFM. Blood 2007; 110(11): 80-81a.
23. Tefferi A, Huang J, Schwager S, et al. Validation and comparison of contemporary prognostic models in primary myelofibrosis: analysis based on 334 patients from a single institution. Cancer 2007; 109(10): 2083-2088. (Pubitemid 46744203)
24. Cervantes F, Dupriez B, Pereira A, et al. A new prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 2008; [epub ahead of print].
25. Strasser-Weippl K, Steurer M, Kees M, et al. Age and hemoglobin level emerge as most important clinical prognostic parameters in patients with osteomyelofibrosis: introduction of a simplified prognostic score. Leuk Lymphoma 2006; 47(3): 441-450. (Pubitemid 43102092)
26. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002; 100(7): 2292-2302.
27. Malcovati L, Porta MG, Pascutto C, et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol 2005; 23(30): 7594-7603. (Pubitemid 46291823)
28. Angelucci E, Turlin B, Canatan D, et al. Iron chelation therapy with deferasirox (Exjade, ICL670) or deferoxaimine is effective in reducing iron overload in patients with advanced fibrosis and cirrhosis. Blood 2005; 106(11): 757a.
29. Davis BA, Porter JB. Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk beta-thalassemia. Blood 2000; 95(4): 1229-1236.
30. Olivieri NF, Nathan DG, MacMillan JH, et al. Survival in medically treated patients with homozygous beta-thalassemia. N Engl J Med 1994; 331(9): 574-578. (Pubitemid 24265699)
31. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89(6): 2079-2088. (Pubitemid 27132124)
32. Takatoku M, Uchiyama T, Okamoto S, et al. Retrospective nationwide survey of Japanese patients with transfusion-dependent MDS and aplastic anemia highlights the negative impact of iron overload on morbidity/mortality. Eur J Haematol 2007; 78(6): 487-494. (Pubitemid 46753591)
33. Jaeger M, Aul C, Sohngen D, Germing U, Schneider W. [Secondary hemochromatosis in polytransfused patients with myelodysplastic syndromes]. Beitr Infusionsther 1992; 30: 464-468.
34. Cazzola M, Barosi G, Gobbi PG, Invernizzi R, Riccardi A, Ascari E. Natural history of idiopathic refractory sideroblastic anemia. Blood 1988; 71(2): 305-312. (Pubitemid 18089515)
35. Gonzalez FA, Arrizabalaga B, Villegas A, et al. Study of deferoxamine in subcutaneous profusion treatment of iron overload in myelodysplastic syndromes. Med Clin (Barc) 2005; 124(17): 645-647. (Pubitemid 40862974)
36. Jensen PD, Jensen FT, Christensen T, Nielsen JL, Ellegaard J. Relationship between hepatocellular injury and transfusional iron overload prior to and during iron chelation with desferrioxamine: a study in adult patients with acquired anemias. Blood 2003; 101(1): 91-96. (Pubitemid 36025892)
37. Tanner MA, Galanello R, Dessi C, et al. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation 2007; 115(14): 1876-1884. (Pubitemid 46598901)
38. Anderson LJ, Westwood MA, Holden S, et al. Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonance. Br J Haematol 2004; 127(3): 348-355. (Pubitemid 39468951)
39. Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. Blood 1997; 89(3): 739-761.
40. Davis BA, O'Sullivan C, Jarritt PH, Porter JB. Value of sequential monitoring of left ventricular ejection fraction in the management of thalassemia major. Blood 2004; 104(1): 263-269. (Pubitemid 38879867)
41. Rahav G, Volach V, Shapiro M, Rund D, Rachmilewitz EA, Goldfarb A. Severe infections in thalassaemic patients: prevalence and predisposing factors. Br J Haematol 2006; 133(6): 667-674. (Pubitemid 43742785)
42. Vento S, Cainelli F. Cesario F. Infections and thalassaemia. Lancet Infect Dis 2006; 6(4): 226-233.
43. Chan LSA, Buckstein R, Reis MD, et al. Iron overload and haematopoiesis in MDS: does blood transfusion promote progression to AML? Blood 2008; 112(11): 928a.
44. Hartmann J, Sinzig U, Wulf G, et al. Evidence for a suppression of the colony forming capacity of erythroid progenitors by iron overload in patients with MDS. Blood 2008; 112(11): 932a.
45. Del Río Garma J, Fernandez LC, Fonrodona BFJ. Desferrioxamine in the treatment of myelodysplastic syndromes. Haematologica 1997; 82(5): 639-640.
46. Jensen PD, Heickendorff L, Pedersen B, et al. The effect of iron chelation on haemopoiesis in MDS patients with transfusional iron overload. Br J Haematol 1996; 94(2): 288-299. (Pubitemid 26247987)
47. Jensen PD, Jensen IM, Ellegaard J. Desferrioxamine treatment reduces blood transfusion requirements in patients with myelodysplastic syndrome. Br J Haematol 1992; 80(1): 121-124.
48. Messa E, Cilloni D, Messa F, Arruga F, Roetto A, Saglio G, Deferasirox treatment improved the hemoglobin level and decreased transfusion requirements in four patients with the myelodysplastic syndrome and primary myelofibrosis. Acta Haematol 2008; 120(2): 70-74.
49. Marsh JH, Hundert M, Schulman P. Deferoxamine-induced restoration of haematopoiesis in myelofibrosis secondary to myelodysplasia. Br J Haematol 1990; 76(1): 148-149. (Pubitemid 20326810)
50. Di Tucci AA, Murru R, Alberti D, Rabault B, Deplano S, Angelucci E. Correction of anemia in a transfusion-dependent patient with primary myelofibrosis receiving iron chelation therapy with deferasirox (Exjade, ICL670). Eur J Haematol 2007; 78(6): 540-542. (Pubitemid 46753589)
51. Smeets ME, Vreugdenhil G, Holdrinet RS. Improvement of erythropoiesis during treatment with deferiprone in a patient with myelofibrosis and transfusional hemosiderosis. Am J Hematol 1996; 51(3): 243-244.
52. Sanz G, Nomdedeu B, Such E, et al. Independent impact of iron overload and transfusion dependency on survival and leukemic evolution in patients with myelodysplastic syndrome. Blood 2008; 112(11): 638-639a.
53. Cervantes F, Alvarez-Larran A, Hernandez-Boluda JC, Sureda A, Torrebadell M, Montserrat E. Erythropoietin treatment of the anaemia of myelofibrosis with myeloid metaplasia: results in 20 patients and review of the literature. Br J Haematol 2004; 127(4): 399-403. (Pubitemid 39536591)
54. Giles FJ, List AF, Carroll M, et al. PTK787/ZK 222584 a small molecule tyrosine kinase receptor inhibitor of vascular endothelial growth factor (VEGF), has modest activity in myelofibrosis with myeloid metaplasia. Leuk Res 2007; 31(7): 891-897. (Pubitemid 46856729)
55. Grandage VL, Everington T, Linch DC, Khwaja A. Go6976 is a potent inhibitor of the JAK 2 and FLT3 tyrosine kinases with significant activity in primary acute myeloid leukaemia cells. Br J Haematol 2006; 135(3): 303-316. (Pubitemid 44484837)
56. Tefferi A, Lasho TL, Mesa RA, Pardanani A, Ketterling RP, Hanson CA. Lenalidomide therapy in del(5)(q31)-associated myelofibrosis: cytogenetic and JAK2V617F molecular remissions. Leukemia 2007; 21(8): 1827-1828.
57. Alessandrino EP, Amadori S, Barosi G, et al. Evidence- and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Hematology. Haematologica 2002; 87(12): 1286-1306.
58. Bowen D, Culligan D, Jowitt S, et al. Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes. Br J Haematol 2003; 120(2): 187-200. (Pubitemid 36194166)
59. Gattermann N. Clinical consequences of iron overload in myelodysplastic syndromes and treatment with chelation. Hematol Oncol Clin North Am 2005; 19(Suppl 1): 13-17.
60. Greenberg PL, Baer MR, Bennett JM, et al. Myelodysplastic syndromes clinical practice guidelines in oncology. J Natl Compr Canc Netw 2006; 4(1): 58-77. (Pubitemid 44265381)
61. Wells RA, Leber B, Buckstein R, et al. Iron overload in myelodysplastic syndromes: a Canadian consensus guideline. Leuk Res 2008; 32(9): 1338-1353.
62. Nearman ZP, Szpurka H, Serio B, et al. Hemochromatosis-associated gene mutations in patients with myelodysplastic syndromes with refractory anemia with ringed sideroblasts. Am J Hematol 2007; 82(12): 1076-1079. (Pubitemid 350209849)
63. Mantovani LG, Scalone L, Ravera S, Rofail D, Cappellini MD. Quality of life and satisfaction with iron chelation therapy in patients with beta thalassemia major: results from the ITHACA study. Blood 2006; 108(11): 954a.
64. Brun-Strang C, Bachir D, Montalembert MD, Thuret I. Socioeconomic impact of infused iron chelation therapy in france: isosfer study results. Blood 2006; 108(11): 957a.